APA (7th ed.) Citation

Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M. Schempp, . . . Lluis Puig. (2024). Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M. Schempp, Kim Petersen, Mia M. Noergaard, and Lluis Puig. Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Adis, Springer Healthcare, 2024.

MLA (9th ed.) Citation

Kristian Reich, et al. Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Adis, Springer Healthcare, 2024.